GoodRx Holdings, Inc. (GDRX) Net Income (Loss) Attributable to Parent USD 2019 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
GoodRx Holdings, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2024.
  • GoodRx Holdings, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$1.01 M, a 69.3% increase year-over-year.
  • GoodRx Holdings, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$6.59 M, a 86.4% increase year-over-year.
  • GoodRx Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$8.87 M, a 73% increase from 2022.
  • GoodRx Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$32.8 M, a 30% decline from 2021.
  • GoodRx Holdings, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$25.3 M, a 91.4% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$6.59 M -$1.01 M +$2.28 M +69.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$8.87 M -$25.9 M -$23.9 M -1212% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 $15 M -$38.5 M +$3.24 M +7.76% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $11.8 M $58.8 M +$60.2 M Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-09
Q1 2023 -$48.4 M -$3.29 M -$15.6 M -127% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$32.8 M -$1.97 M +$37.9 M +95.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$70.8 M -$41.7 M -$23.7 M -131% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$47.1 M -$1.42 M -$32.5 M -105% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$14.6 M $12.3 M +$10.6 M +637% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$25.3 M -$39.9 M +$258 M +86.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$284 M -$18.1 M +$32 M +63.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 -$316 M $31.1 M +$3.72 M +13.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 -$319 M $1.67 M -$25.7 M -93.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 -$294 M -$298 M -$314 M -2059% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $19.9 M -$50 M -$69.7 M -355% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $89.5 M $27.3 M +$7.69 M +39.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 $81.8 M $27.3 M +$15.8 M +137% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 $66 M $15.2 M Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $19.6 M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $19.7 M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 $11.6 M Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.